Alessandra De Gregorio1, Emilio Pedrotti2, Luisa Russo3, Simonetta Morselli3. 1. Ophthalmic Unit, San Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Vicenza, Italy. adegre3@gmail.com. 2. Eye Clinic, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy. 3. Ophthalmic Unit, San Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Vicenza, Italy.
Abstract
PURPOSE: To verify the efficacy in intraocular pressure (IOP) reduction and safety of the smallest gel stent (XEN 45 Gel Stent) microincisional glaucoma surgery combined with microincisional cataract surgery (MICS). METHODS: Nonrandomized prospective clinical study. Forty-one eyes of 33 patients with open-angle glaucoma underwent a XEN 45 Gel Stent implantation combined with MICS. Treatment outcomes analyzed included: IOP, medication use, intra- and postoperative complications. At the end of the follow-up, we evaluated the complete success, defined as a postoperative IOP ≥ 6 and ≤17 mmHg without glaucoma medications and the qualified success defined as a postoperative IOP ≥ 6 and ≤17 mmHg, with glaucoma medications. RESULTS: The mean preoperative IOP was 22.5 ± 3.7 mmHg on 2.5 ± 0.9 medication classes. After 12 months, the mean postoperative IOP was 13.1 ± 2.4 mmHg (mean IOP reduction of 41.82%) with a mean of 0.4 ± 0.8 medication classes (P < 0.05 for IOP and medications). The complete success rate was achieved in 80.4% and a qualified success in 97.5%. There were no major intra- and postoperative complications during the first year of follow-up. CONCLUSIONS: This study demonstrated that the smaller diameter XEN 45 gel implant is statistically effective in reducing IOP and medications in glaucoma patients with a low rate of complications.
PURPOSE: To verify the efficacy in intraocular pressure (IOP) reduction and safety of the smallest gel stent (XEN 45 Gel Stent) microincisional glaucoma surgery combined with microincisional cataract surgery (MICS). METHODS: Nonrandomized prospective clinical study. Forty-one eyes of 33 patients with open-angle glaucoma underwent a XEN 45 Gel Stent implantation combined with MICS. Treatment outcomes analyzed included: IOP, medication use, intra- and postoperative complications. At the end of the follow-up, we evaluated the complete success, defined as a postoperative IOP ≥ 6 and ≤17 mmHg without glaucoma medications and the qualified success defined as a postoperative IOP ≥ 6 and ≤17 mmHg, with glaucoma medications. RESULTS: The mean preoperative IOP was 22.5 ± 3.7 mmHg on 2.5 ± 0.9 medication classes. After 12 months, the mean postoperative IOP was 13.1 ± 2.4 mmHg (mean IOP reduction of 41.82%) with a mean of 0.4 ± 0.8 medication classes (P < 0.05 for IOP and medications). The complete success rate was achieved in 80.4% and a qualified success in 97.5%. There were no major intra- and postoperative complications during the first year of follow-up. CONCLUSIONS: This study demonstrated that the smaller diameter XEN 45 gel implant is statistically effective in reducing IOP and medications in glaucomapatients with a low rate of complications.
Entities:
Keywords:
Filtration surgery; Glaucoma; Microincisional glaucoma surgery (MIGS); XEN Gel Stent
Authors: Thomas S Shute; Ursula M Dietrich; Julia F M Baker; K Paige Carmichael; William Wustenberg; Iqbal Ike K Ahmed; Arsham Sheybani Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Arsham Sheybani; Markus Lenzhofer; Melchior Hohensinn; Herbert Reitsamer; Iqbal Ike K Ahmed Journal: J Cataract Refract Surg Date: 2015-10-23 Impact factor: 3.351
Authors: Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng Journal: Ophthalmology Date: 2014-06-26 Impact factor: 12.079
Authors: Michael M Lin; William H Morgan; Natasha N Kolomeyer; Stephen J Moster; Cindy X Zheng; Antonio Giubilato; Marlene R Moster Journal: J Glaucoma Date: 2019-12 Impact factor: 2.503
Authors: Miguel A Teus; Javier Paz Moreno-Arrones; Beatriz Castaño; Miguel A Castejon; Gema Bolivar Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-02-20 Impact factor: 3.117
Authors: Anna Do; Elyse McGlumphy; Aakriti Shukla; Sonal Dangda; Joel S Schuman; Michael V Boland; Jithin Yohannan; Joseph F Panarelli; E Randy Craven Journal: Ophthalmol Glaucoma Date: 2020-12-13